350 related articles for article (PubMed ID: 22225906)
1. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
[TBL] [Abstract][Full Text] [Related]
2. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Brady S; Gao H; Yu D; Reuben J; Mehta K
PLoS One; 2010 Oct; 5(10):e13390. PubMed ID: 20967228
[TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
Agnihotri N; Kumar S; Mehta K
Breast Cancer Res; 2013 Feb; 15(1):202. PubMed ID: 23673317
[TBL] [Abstract][Full Text] [Related]
5. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells.
Celià-Terrassa T; Meca-Cortés O; Mateo F; Martínez de Paz A; Rubio N; Arnal-Estapé A; Ell BJ; Bermudo R; Díaz A; Guerra-Rebollo M; Lozano JJ; Estarás C; Ulloa C; Álvarez-Simón D; Milà J; Vilella R; Paciucci R; Martínez-Balbás M; de Herreros AG; Gomis RR; Kang Y; Blanco J; Fernández PL; Thomson TM
J Clin Invest; 2012 May; 122(5):1849-68. PubMed ID: 22505459
[TBL] [Abstract][Full Text] [Related]
9. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
Lin CY; Tsai PH; Kandaswami CC; Chang GD; Cheng CH; Huang CJ; Lee PP; Hwang JJ; Lee MT
Mol Cancer; 2011 Jul; 10():87. PubMed ID: 21777419
[TBL] [Abstract][Full Text] [Related]
10. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.
Morel AP; Hinkal GW; Thomas C; Fauvet F; Courtois-Cox S; Wierinckx A; Devouassoux-Shisheboran M; Treilleux I; Tissier A; Gras B; Pourchet J; Puisieux I; Browne GJ; Spicer DB; Lachuer J; Ansieau S; Puisieux A
PLoS Genet; 2012; 8(5):e1002723. PubMed ID: 22654675
[TBL] [Abstract][Full Text] [Related]
11. Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway.
Kumar S; Mehta K
PLoS One; 2012; 7(11):e49321. PubMed ID: 23185316
[TBL] [Abstract][Full Text] [Related]
12. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures.
Leibovich-Rivkin T; Liubomirski Y; Bernstein B; Meshel T; Ben-Baruch A
Neoplasia; 2013 Dec; 15(12):1330-46. PubMed ID: 24403855
[TBL] [Abstract][Full Text] [Related]
14. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.
Shao M; Cao L; Shen C; Satpathy M; Chelladurai B; Bigsby RM; Nakshatri H; Matei D
Cancer Res; 2009 Dec; 69(24):9192-201. PubMed ID: 19951993
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.
Han AL; Kumar S; Fok JY; Tyagi AK; Mehta K
Eur J Cancer; 2014 Jun; 50(9):1685-96. PubMed ID: 24656569
[TBL] [Abstract][Full Text] [Related]
18. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties.
Sarrio D; Franklin CK; Mackay A; Reis-Filho JS; Isacke CM
Stem Cells; 2012 Feb; 30(2):292-303. PubMed ID: 22102611
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
Mehta K; Kumar A; Kim HI
Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.
Davidowitz RA; Selfors LM; Iwanicki MP; Elias KM; Karst A; Piao H; Ince TA; Drage MG; Dering J; Konecny GE; Matulonis U; Mills GB; Slamon DJ; Drapkin R; Brugge JS
J Clin Invest; 2014 Jun; 124(6):2611-25. PubMed ID: 24762435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
